BIONTECH: Looking forward to potential EUA in 4Q20 and additional updates from oncology franchise | BUY | USD98
BIONTECH - BUY | USD98Looking forward to potential EUA in 4Q20 and additional updates from oncology franchise
Looking ahead of potential EUA filing in Q4 2020
Major steps in manufacturing scale-up could be expected in 1H21
We also note that during the Q3 call, BioNTech mentioned changes in the manufacturing (specifically mRNA purification) that took place during the scale-up process, albeit pointing that the purification processes are comparable and all necessary documentation has been already submitted to the FDA and EMA.
Thoughts around BNT162b2 distribution
SITC20 provides the first look on BNT311
More updates from oncology franchise in 2020
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.